Kymera Therapeutics, Inc. (NASDAQ:KYMR) Shares Sold by Marshall Wace LLP

Marshall Wace LLP trimmed its stake in shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR) by 34.3% during the 2nd quarter, Holdings Channel reports. The fund owned 376,562 shares of the company’s stock after selling 196,364 shares during the quarter. Marshall Wace LLP’s holdings in Kymera Therapeutics were worth $11,240,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors also recently bought and sold shares of the company. Price T Rowe Associates Inc. MD boosted its position in Kymera Therapeutics by 18.7% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 6,332,012 shares of the company’s stock worth $254,548,000 after purchasing an additional 996,300 shares in the last quarter. Vanguard Group Inc. lifted its stake in shares of Kymera Therapeutics by 19.2% in the 1st quarter. Vanguard Group Inc. now owns 4,767,050 shares of the company’s stock valued at $191,635,000 after purchasing an additional 769,486 shares during the period. Norges Bank purchased a new stake in Kymera Therapeutics during the fourth quarter worth $12,834,000. Artal Group S.A. grew its position in Kymera Therapeutics by 19.6% during the first quarter. Artal Group S.A. now owns 3,027,135 shares of the company’s stock valued at $121,691,000 after buying an additional 496,400 shares during the period. Finally, Goldman Sachs Group Inc. increased its holdings in Kymera Therapeutics by 229.6% in the fourth quarter. Goldman Sachs Group Inc. now owns 674,655 shares of the company’s stock valued at $17,177,000 after buying an additional 469,947 shares in the last quarter.

Wall Street Analyst Weigh In

A number of research firms have recently commented on KYMR. Leerink Partners restated an “outperform” rating and set a $60.00 target price on shares of Kymera Therapeutics in a research report on Monday, September 9th. HC Wainwright reissued a “buy” rating and issued a $46.00 price objective on shares of Kymera Therapeutics in a report on Monday, June 17th. Morgan Stanley upped their target price on Kymera Therapeutics from $34.00 to $45.00 and gave the stock an “equal weight” rating in a research note on Wednesday, August 14th. Wells Fargo & Company lifted their price target on shares of Kymera Therapeutics from $30.00 to $38.00 and gave the company an “equal weight” rating in a research note on Monday, August 12th. Finally, Oppenheimer upped their price objective on shares of Kymera Therapeutics from $52.00 to $56.00 and gave the stock an “outperform” rating in a research report on Friday. Four research analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, Kymera Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus price target of $49.00.

Insiders Place Their Bets

In other news, Director Bruce Booth sold 453,960 shares of the firm’s stock in a transaction that occurred on Tuesday, July 9th. The shares were sold at an average price of $38.21, for a total transaction of $17,345,811.60. Following the completion of the sale, the director now owns 723,246 shares in the company, valued at approximately $27,635,229.66. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. In related news, Director Jeffrey W. Albers sold 5,000 shares of the business’s stock in a transaction dated Monday, August 26th. The shares were sold at an average price of $49.10, for a total value of $245,500.00. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Bruce Booth sold 453,960 shares of the company’s stock in a transaction dated Tuesday, July 9th. The shares were sold at an average price of $38.21, for a total transaction of $17,345,811.60. Following the completion of the transaction, the director now directly owns 723,246 shares in the company, valued at approximately $27,635,229.66. The disclosure for this sale can be found here. Insiders have sold 495,605 shares of company stock valued at $19,303,364 over the last ninety days. Company insiders own 15.82% of the company’s stock.

Kymera Therapeutics Trading Down 1.6 %

KYMR opened at $48.69 on Friday. Kymera Therapeutics, Inc. has a twelve month low of $9.60 and a twelve month high of $53.27. The firm has a market capitalization of $2.99 billion, a PE ratio of -19.40 and a beta of 2.22. The firm’s 50-day moving average price is $45.79 and its 200 day moving average price is $39.35.

Kymera Therapeutics (NASDAQ:KYMR) last issued its earnings results on Wednesday, August 7th. The company reported ($0.58) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.68) by $0.10. Kymera Therapeutics had a negative return on equity of 28.88% and a negative net margin of 178.27%. The business had revenue of $25.60 million during the quarter, compared to the consensus estimate of $12.55 million. During the same period last year, the company earned ($0.67) EPS. The company’s revenue for the quarter was up 55.2% on a year-over-year basis. As a group, analysts predict that Kymera Therapeutics, Inc. will post -2.87 earnings per share for the current fiscal year.

Kymera Therapeutics Profile

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.